BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 8516604)

  • 1. Histopathologic study of recurrent Clark level II melanomas.
    Glass LF; Guffey JM; Schroer KR; Reintgen D
    Semin Surg Oncol; 1993; 9(3):202-7. PubMed ID: 8516604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of higher risk thin melanomas should be based on Breslow depth not Clark level IV.
    Owen SA; Sanders LL; Edwards LJ; Seigler HF; Tyler DS; Grichnik JM
    Cancer; 2001 Mar; 91(5):983-91. PubMed ID: 11251950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acral lentiginous melanoma: histopathological prognostic features of 121 cases.
    Phan A; Touzet S; Dalle S; Ronger-Savlé S; Balme B; Thomas L
    Br J Dermatol; 2007 Aug; 157(2):311-8. PubMed ID: 17596173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breslow thickness and clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer Staging.
    Marghoob AA; Koenig K; Bittencourt FV; Kopf AW; Bart RS
    Cancer; 2000 Feb; 88(3):589-95. PubMed ID: 10649252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas.
    Cherpelis BS; Haddad F; Messina J; Cantor AB; Fitzmorris K; Reintgen DS; Fenske NA; Glass LF
    J Am Acad Dermatol; 2001 May; 44(5):762-6. PubMed ID: 11312421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma.
    Clemente CG; Mihm MC; Bufalino R; Zurrida S; Collini P; Cascinelli N
    Cancer; 1996 Apr; 77(7):1303-10. PubMed ID: 8608507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Independent prognostic importance of vascular invasion in nodular melanomas.
    Straume O; Akslen LA
    Cancer; 1996 Sep; 78(6):1211-9. PubMed ID: 8826942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.
    Vitoux D; Mourah S; Kerob D; Verola O; Basset-Seguin N; Baccard M; Schartz N; Ollivaud L; Archimbaud A; Servant JM; Revol M; Toubert ME; Podgorniak MP; Plassa F; Porcher R; Lebbé C
    Arch Dermatol; 2009 Oct; 145(10):1105-13. PubMed ID: 19841396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathologic and clinical features influencing outcome of thin cutaneous melanoma: correlation with newly proposed staging system.
    Finley JW; Gibbs JF; Rodriguez LM; Letourneau R; Driscoll D; Kraybill W
    Am Surg; 2000 Jun; 66(6):527-31; discussion 531-2. PubMed ID: 10888127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study.
    Barnhill RL; Fine JA; Roush GC; Berwick M
    Cancer; 1996 Aug; 78(3):427-32. PubMed ID: 8697387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sentinel lymph node biopsy for the T1 (thin) melanoma: is it necessary?
    Nahabedian MY; Tufaro AP; Manson PN
    Ann Plast Surg; 2003 Jun; 50(6):601-6. PubMed ID: 12783009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous melanomas that defy conventional prognostic indicators.
    McCarthy WH; Shaw HM; McCarthy SW; Rivers JK; Thompson JF
    Semin Oncol; 1996 Dec; 23(6):709-13. PubMed ID: 8970591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
    Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L
    Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic importance of sentinel lymph node biopsy in thin melanoma.
    Ranieri JM; Wagner JD; Wenck S; Johnson CS; Coleman JJ
    Ann Surg Oncol; 2006 Jul; 13(7):927-32. PubMed ID: 16788753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors of cutaneous melanoma in relation to metastasis at the sentinel lymph node: a case-controlled study.
    Sartore L; Papanikolaou GE; Biancari F; Mazzoleni F
    Int J Surg; 2008 Jun; 6(3):205-9. PubMed ID: 18417434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective observational study of primary cutaneous malignant melanoma patients treated with excision only compared with excision biopsy followed by wider local excision.
    McKenna DB; Lee RJ; Prescott RJ; Doherty VR
    Br J Dermatol; 2004 Mar; 150(3):523-30. PubMed ID: 15030337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.
    Taylor RC; Patel A; Panageas KS; Busam KJ; Brady MS
    J Clin Oncol; 2007 Mar; 25(7):869-75. PubMed ID: 17327608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interobserver variation in the histopathologic reporting of key prognostic parameters, particularly clark level, affects pathologic staging of primary cutaneous melanoma.
    Murali R; Hughes MT; Fitzgerald P; Thompson JF; Scolyer RA
    Ann Surg; 2009 Apr; 249(4):641-7. PubMed ID: 19300224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Important prognostic significance of a sentinel-node biopsy in patients with malignant melanoma].
    Keijzer R; Bril H; van der Loo EM; de Graaf PW
    Ned Tijdschr Geneeskd; 2004 May; 148(18):884-8. PubMed ID: 15152391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Desmoplastic malignant melanoma: a clinicopathologic analysis of 113 cases.
    de Almeida LS; Requena L; Rütten A; Kutzner H; Garbe C; Pestana D; Gomes MM
    Am J Dermatopathol; 2008 Jun; 30(3):207-15. PubMed ID: 18496419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.